19 April 2021 – Further National Microbiology Framework contract award

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Further National Microbiology Framework contract award

Successful tender under Lot 4 (Clinical Laboratory Diagnostic Testing Services) valued at £15bn

Manchester, UK – 19 April 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Public Health England (“PHE”) has confirmed that Yourgene has been successful with its tender under PHE’s National Microbiology Framework for Lot 4 (Clinical Laboratory Diagnostic Testing Services).

Lot 4 is a £15bn Framework to be satisfied over a period of four years by multiple successful bidders, with only 50 companies appointed to this lot.

PHE’s National Microbiology Framework is appointing suppliers to framework agreements for four lots. Awards under Lot 1 and Lot 4 have been announced and cover the supply of Diagnostics Goods and Services, including Clinical Laboratory Diagnostic Testing Services. Yourgene announced earlier today that it had been successful with its tender for Lot 1 (Diagnostic Goods and Services).

Yourgene will be able to offer its Clarigene® SARS-CoV-2 PCR assay and associated Manchester-based clinical laboratory testing services under the Framework Agreement.

Whilst the Framework Agreement is not exclusive to Yourgene, or a guarantee of orders, it does allow participating public health authorities across the UK to issue call-off contracts to procure goods and testing services from Yourgene, amongst other providers, going forward.

Lyn Rees, CEO of Yourgene commented:
“We are delighted with the further successful tender award under Lot 4 of the Microbiology Framework. This reinforces the reputation of our accredited lab based COVID testing services and we look forward to updating shareholders should we secure future call-off contracts under this framework agreement.”

This announcement contains inside information for the purposes of UK Market Abuse Regulation. The Directors of the Company take responsibility for this announcement.

Yourgene Health plc

Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing

Tel: +44 (0)161 669 8122


Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie / Ludovico Lazzaretti

 Tel: +44 (0)20 7213 0880

N+1 Singer (Joint Corporate Broker)
Aubrey Powell / Tom Salvesen / George Tzimas

Tel: +44 (0)20 7496 3000

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Nicholas Moore / Matthew Blawat / Ben Maddison

Tel: +44 (0)20 7710 7600

Walbrook PR Ltd (Media and Investor Relations)

Paul McManus / Lianne Cawthorne 

Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com

Mob: 07980 541 893 Mob: 07584 391 303   

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group’s flagship products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene’s geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.